Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta
Georgia
30005
United States
Tel: 678-270-3631
Fax: 678-270-4033
Website: http://www.clearsidebio.com/
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Stock Symbol: CLSD
Stock Exchange: NASDAQ
148 articles with Clearside Biomedical, Inc.
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/9/2023
Clearside Biomedical, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
-
Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023
2/23/2023
Clearside Biomedical, Inc. announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets.
-
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
2/21/2023
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that several presentations were delivered at two prestigious medical conferences in February: the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting.
-
Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
2/7/2023
Clearside Biomedical, Inc. announced today that data from the Company’s OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) will be presented at the following medical meetings in February 2023.
-
Clearside Biomedical Announces Leadership Team Update
2/6/2023
Clearside Biomedical, Inc. today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023.
-
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
2/2/2023
Clearside Biomedical, Inc. announced today positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in neovascular age-related macular degeneration (wet AMD) participants.
-
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
11/22/2022
Clearside Biomedical, Inc. announced today that management will participate in the following conferences in November and December 2022.
-
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
11/10/2022
Clearside Biomedical, Inc. announced that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time, in New York, NY.
-
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
11/9/2022
Clearside Biomedical, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
11/9/2022
Clearside Biomedical, Inc. announced today positive results from its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in neovascular age-related macular degeneration (wet AMD) patients.
-
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
11/8/2022
Clearside Biomedical, Inc. announced that the Company will host a conference call on Wednesday, November 9, 2022 at 8:30 a.m. Eastern Time to report results from its OASIS Phase 1/2a clinical trial of CLS-AX in neovascular age-related macular degeneration patients.
-
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
11/2/2022
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets.
-
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
10/4/2022
Clearside Biomedical, Inc. announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons.
-
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
9/27/2022
Clearside Biomedical, Inc. announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a corporate overview at the Eyecelerator conference on September 29, 2022, as part of the Annual Meeting of the American Academy of Ophthalmology, the world's largest association of eye physicians and surgeons.
-
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
8/25/2022
Clearside Biomedical, Inc. announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.
-
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million- Transaction Supports Progression of CLS-AX Clinical Program -
8/8/2022
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today it has entered into a Royalty Interest Purchase and Sale Agreement (the agreement) with HealthCare Royalty Partners (HealthCare Royalty).
-
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
7/26/2022
Clearside Biomedical, Inc. announced today completion of dosing in Cohorts 3 and 4 of OASIS, its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
-
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
6/14/2022
Clearside Biomedical, Inc. today announced the appointment of Susan L. Coultas, Ph.D., as Chief Clinical Officer.
-
Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference
6/8/2022
Clearside Biomedical, Inc. announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022, at 9:30 a.m. Eastern Time, in New York, NY.
-
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update
5/11/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.